(Q33410172)

English

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

object named as

Albert Oriol

10

0 references

object named as

Michele Cavo

13

0 references

Jesús San Miguel

object named as

Jesus San Miguel

1

0 references

Athanasios Dimopoulos

object named as

Meletios Dimopoulos

25

0 references

4

object named as

Martha Lacy

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pieter Sonneveld

20

object named as

Pieter Sonneveld

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Philippe Moreau

3

object named as

Philippe Moreau

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hartmut Goldschmidt

8

object named as

Hartmut Goldschmidt

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Antonio Palumbo

18

object named as

Antonio Palumbo

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

object named as

Katja Weisel

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Laurent Garderet

14

object named as

Laurent Garderet

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

17

object named as

Andrew Belch

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michel Delforge

6

object named as

Michel Delforge

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

7

object named as

Lionel Karlin

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9

object named as

Anne Banos

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Adrian Alegre-Sanchez

11

object named as

Adrian Alegre

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

19

object named as

Stephen Schey

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

22

object named as

Lars Sternas

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Kevin Song

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christine Chen

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Valentina Ivanova

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joaquin Martinez-Lopez

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Xin Yu

21

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christian Jacques

23

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mohamed Zaki

24

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

3 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1055-1066

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970380-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970380-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970380-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970380-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970380-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970380-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970380-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinically relevant end points and new drug approvals for myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970380-2

7 January 2021

based on heuristic

inferred from DOI database lookup

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970380-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970380-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970380-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970380-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970380-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970380-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70380-2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33410172&oldid=1958995263"